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Abstract: Background Direct bronchial spread of tuberculosis was extensively described in pre-antibiotic
human pathology literature but this description has been overlooked in the post-antibiotic era, in which
most pathology data come from animal models that emphasise the granuloma. Modern techniques, such
as [18F]2-fluoro-2-deoxy-D-glucose (FDG) PET-CT scans, might provide further insight. Our aim was to
understand normal early tuberculosis resolution patterns on pulmonary PET-CT scans in treated patients
with tuberculosis who were subsequently cured. Methods In this observational analysis, we analysed data
from PredictTB, an ongoing, prospective, randomised clinical trial that examined sequential baseline and
week 4 FDG-PET-CT scans from participants successfully treated (sputum culture negative 18 months
after enrolment) for drug-susceptible pulmonary tuberculosis in South Africa and China. Participants
who were aged 18–75 years, GeneXpert MTB/RIF positive for tuberculosis and negative for rifampicin
resistance, had not yet started tuberculosis treatment, had not been treated for active tuberculosis within
the previous 3 years, and met basic safety laboratory criteria were included and participants with diabetes,
HIV infection, or with extrapulmonary tuberculosis including pleural tuberculosis were excluded. Scans
were assessed by two readers for the location of tuberculosis lesions (eg, cavities and consolidations),
bronchial thickening patterns, and changes from baseline to week 4 of treatment. Findings Among the
first 124 participants (enrolled from June 22, 2017, to Sept 27, 2018) who were successfully treated, 161
primarily apical cavitary lesions were identified at baseline. Bronchial thickening and inflammation linking
non-cavitary consolidative lesions to cavities were observed in 121 (98%) of 124 participants’ baseline
PET-CT scans. After 4 weeks of treatment, 21 (17%) of 124 participants had new or expanding lesions
linked to cavities via bronchial inflammation that were not present at baseline, particularly participants
with two or more cavities at baseline and participants from South Africa. Interpretation In participants
with pulmonary tuberculosis who were subsequently cured, the location of cavitary and non-cavitary
lesions at baseline and new lesions at week 4 of treatment suggest a cavitary origin of disease and
bronchial spread through the lungs. Bronchial spread from cavities might play a larger role in the
spread of pulmonary tuberculosis than has been appreciated. Elucidating cavity lesion dynamics and
Mycobacterium tuberculosis viability within cavities might better explain treatment outcomes and why
some patients are cured and others relapse. Funding Bill Melinda Gates Foundation, European and
Developing Countries Clinical Trials Partnership, China Ministry of Science and Technology, National
Natural Science Foundation of China, and National Institutes of Health. Translations For the Chinese,
Afrikaans and Xhosa translations of the abstract see Supplementary Materials section
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Summary
Background Direct bronchial spread of tuberculosis was extensively described in pre-antibiotic human pathology 
literature but this description has been overlooked in the post-antibiotic era, in which most pathology data come from 
animal models that emphasise the granuloma. Modern techniques, such as [¹⁸F]2-fluoro-2-deoxy-D-glucose (FDG) 
PET-CT scans, might provide further insight. Our aim was to understand normal early tuberculosis resolution 
patterns on pulmonary PET-CT scans in treated patients with tuberculosis who were subsequently cured.
Methods In this observational analysis, we analysed data from PredictTB, an ongoing, prospective, randomised 
clinical trial that examined sequential baseline and week 4 FDG-PET-CT scans from participants successfully treated 
(sputum culture negative 18 months after enrolment) for drug-susceptible pulmonary tuberculosis in South Africa 
and China. Participants who were aged 18–75 years, GeneXpert MTB/RIF positive for tuberculosis and negative for 
rifampicin resistance, had not yet started tuberculosis treatment, had not been treated for active tuberculosis within 
the previous 3 years, and met basic safety laboratory criteria were included and participants with diabetes, HIV 
infection, or with extrapulmonary tuberculosis including pleural tuberculosis were excluded. Scans were assessed by 
two readers for the location of tuberculosis lesions (eg, cavities and consolidations), bronchial thickening patterns, 
and changes from baseline to week 4 of treatment.
Findings Among the first 124 participants (enrolled from June 22, 2017, to Sept 27, 2018) who were successfully 
treated, 161 primarily apical cavitary lesions were identified at baseline. Bronchial thickening and inflammation 
linking non-cavitary consolidative lesions to cavities were observed in 121 (98%) of 124 participants’ baseline 
PET-CT scans. After 4 weeks of treatment, 21 (17%) of 124 participants had new or expanding lesions linked to cavities 
via bronchial inflammation that were not present at baseline, particularly participants with two or more cavities at 
baseline and participants from South Africa.
Interpretation In participants with pulmonary tuberculosis who were subsequently cured, the location of cavitary and 
non-cavitary lesions at baseline and new lesions at week 4 of treatment suggest a cavitary origin of disease and 
bronchial spread through the lungs. Bronchial spread from cavities might play a larger role in the spread of pulmonary 
tuberculosis than has been appreciated. Elucidating cavity lesion dynamics and Mycobacterium tuberculosis viability 
within cavities might better explain treatment outcomes and why some patients are cured and others relapse.
Funding Bill & Melinda Gates Foundation, European and Developing Countries Clinical Trials Partnership, China 
Ministry of Science and Technology, National Natural Science Foundation of China, and National Institutes of 
Health.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Tuberculosis infection has traditionally been described in 
two stages, latent or active. In the past 5 years, reviews of 
tuberculosis, however, have begun to view infection more 
as a continuum rather than distinct, dichotomous stages. 
Driven by data from rabbits and non-human primates, 
it is thought that Mycobacterium tuberculosis bacilli 
contained in granulomas begin to replicate and erode 
into a bronchus, forming a cavity that then allows 
transmission until symptoms emerge and a patient is 
treated.1,2 However, pathological descriptions of autopsy 
specimens that were commonly done during the 
pre-antibiotic era, up to the 1950s, from patients who 
died of tuberculosis identified a more complex natural 
history of disease progression. Pathologists of that time 
recognised that primary tuberculosis infection generally 
did not lead to active tuberculosis but rather was most 
often controlled within a granuloma or the hilar lymph 
nodes. The resumption of M tuberculosis bacillary repli-
cation followed by spread within the lungs eventually led 
to active tuberculosis and its spread. Multiple authors 
noted that cavities formed from a caseous focus of 
infection that progressed to liquefactive necrosis. When 
such a lesion expanded and eroded into a bronchus, air 
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entered the lesion to form a cavity and the liquefied 
lesion contents were released through the bronchus to 
infect other parts of the lungs, causing bronchogenic 
consolidations.3–10 These observations from over 60 years 
ago provide key insights into how active tuberculosis 
often originates in lesions that become cavities, with 
bronchial spread of liquefied cavity contents causing 
disease elsewhere in the lungs and passing out through 
the mouth as phlegm or sputum. The pathologists of 
the time thus recognised that cavity appearance and 
formation was inextricably linked to bronchial spread 
within the patient and to subsequent transmission.3,7–9,11,12
With the advent of effective chemotherapy starting in 
the 1950s, tuberculosis mortality dropped substantially 
such that, by the 1970s, mortality rates were so low that 
studies based on autopsy specimens were no longer 
practical.13 Pathology studies thereafter relied primarily 
on animal models, particularly rabbits, guinea pigs, and 
non-human primates, which develop extensive pathology. 
These models focused attention on the granuloma, a 
hallmark of primary tuberculosis infection, rather than 
on caseous pneumonias with cavitation and bronchial 
spread, seen in reactivation tuberculosis.14–18 There are 
few human pathology specimens available today to 
corroborate or refute the earlier studies, but data other 
than pathology might be informative. One analysis 
using [¹⁸F]2-fluoro-2-deoxy-D-glucose (FDG) PET-CT 
scans showed that new or worsening lesions appeared on 
the end-of-treatment month 6 scan in 34 (34%) of 
99 participants treated in South Africa,19 suggesting that 
M tuberculosis might still be viable and possibly spreading 
among apparently cured patients. Although all eight 
participants with treatment failure had this mixed 
response pattern, so did 21 (28%) of the 76 cured 
participants, showing the poor prognostic specificity of 
this pattern. A better understanding of the patho physiol-
ogy behind these response patterns on PET-CT scans is 
needed to know how to interpret such new and seemingly 
worsening lesions that appear during treatment. To 
under stand what treatment response patterns are 
associated with poor outcomes, we first need to understand 
the temporal range of patterns seen in eventually cured 
patients: tuberculosis pathology patterns on the baseline 
scan and how those patterns change during treatment. 
We are doing a tuberculosis clinical trial during which 
FDG-PET-CT scans are done at baseline and during 
treatment of patients with active tuberculosis. The aim of 
this analysis is to understand baseline and early 
tuberculosis treatment response patterns on pulmonary 
PET-CT scans in patients who are subsequently cured.
Methods
Study design and participants
The ongoing, prospective, randomised clinical trial Using 
Biomarkers to Predict TB Treatment Duration (PredictTB, 
NCT02821832) is a tuberculosis treatment-shortening 
study in participants with pulmonary, drug-sensitive 
tuberculosis with serial FDG-PET with high resolution 
non-contrast chest CT scans done at baseline, week 4 of 
treatment, and then at either week 16 or 24. Participants 
were enrolled in the Western Cape, South Africa, and in 
Henan Province, China, and were followed up until week 
72 for final treatment outcomes. Full details of the study 
design, enrolment sites, inclusion and exclusion criteria, 
Research in context
Evidence before this study
Many radiology and pathology studies in patients with 
tuberculosis have been done previously. We searched PubMed 
for the terms “bronchial spread” or “bronchogenic spread” and 
“tuberculosis” from database inception to Dec 15, 2020, with 
no language restrictions. 89 articles were identified. These 
articles and their references were searched, as well as three 
available tuberculosis textbooks from the 1940s and 1950s. In 
studies of CT scans of patients with pulmonary tuberculosis, 
bronchogenic spread is described as nodular lesions or with the 
tree-in-bud sign. However, multiple pathology studies done 
before 1950 before the advent of tuberculosis chemotherapy 
suggested that bronchial spread of tuberculosis originated from 
cavities and caused much more severe disease including 
consolidations. With the arrival of effective tuberculosis 
chemotherapy, autopsies of patients with tuberculosis were 
generally no longer done. Animal models of tuberculosis were 
used instead but these models did not effectively reflect the 
reactivation tuberculosis that is most commonly seen in human 
adults with tuberculosis, leading to a shift in focus to the 
tuberculosis granuloma rather than the cavity.
Added value of this study
Historical pathological autopsy descriptions of human 
pulmonary tuberculosis have never been correlated with 
modern radiological studies to inform our understanding of the 
pulmonary tuberculosis pathology seen radiologically.
Before starting treatment, 121 (98%) of 124 participants in our 
study who were eventually cured of their pulmonary 
tuberculosis showed patterns on PET-CT scans consistent with 
bronchial spread of tuberculosis, primarily from cavities but 
occasionally from consolidations. This finding supports the 
older pathology literature. 21 (17%) of 124 particiants showed 
apparently worsening bronchial spread patterns (new or 
expanding lesions) 4 weeks after starting treatment, despite 
being subsequently cured.
Implications of all the available evidence
Cavities might spread tuberculosis disease to other parts of 
the lungs through the bronchi. Elucidating cavity lesion 
dynamics, including Mycobacterium tuberculosis viability 
within cavities, might be critical to better understanding 
treatment outcomes.
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randomisation schema, statistical methods, and how 
PET-CT scans were done have been previously published.20 
The study included patients aged 18–75 years (upper limit 
increased from 65 years during the trial to increase the 
enrolment rate), who were GeneXpert MTB/RIF positive 
for tuberculosis and negative for rifampicin resistance, 
had not yet started tuberculosis treatment, had not been 
treated for active tuberculosis within the previous 3 years, 
and met basic safety laboratory criteria. Participants with 
diabetes, HIV infection, or with extrapulmonary tuber-
culosis including pleural tuberculosis were exclu ded. 
Baseline PET-CT scans were done within 7 days of 
participant enrolment with the second scan done 4 weeks 
later (with a minus 3-day to plus 7-day window). Signed 
informed consent was obtained from each participant. 
This study was approved by the institutional review board 
(IRB) of the US National Institute of Allergy and 
Infectious Diseases (NIAID) and the IRB or ethics 
committee of each enrolling site. The first 124 participants 
cured in the trial (defined as sputum cultures that 
remained negative up until week 72), without regard to 
study arm assignment, were included in this observational 
analysis. This analysis is not related to the primary 
objective of the parent clinical trial.
Procedures and statistical analysis
PET-CT scans were analysed using MIM version 6.7 
(MIM Software, Cleveland, OH, USA) and Amira 
version 6.5 (Thermo Fisher Scientific, Waltham, MA, 
USA). Baseline characteristics between groups were 
analysed by t test for continuous variables and χ² test 
or Fisher’s exact test for categorical variables, with 
significance defined as p<0∙05. Variables significant 
in the univariate model were tested together in a multi-
variate logistic regression model. A bronchial spread 
pattern of tuberculosis was defined as direct connections 
through inflamed or thickened bronchi between cavities, 
typically located in apical pulmonary segments of the 
upper or lower lobes, and consolidations, typically in 
dependent locations inferior to the cavities. Two readers 
(RYC and CEB III) independently assessed the segmental 
location of cavities and connected lesions, with incon-
sistencies resolved by consensus. Cavity volumes within 
individual segments were summed. The likelihood of 
bronchial spread to an inferior versus superior lung 
segment was tested by the Clopper-Pearson binomial test. 
R version 4.0.2 was used for the statistical analyses.
Sputum was collected from study participants at every 
follow-up visit and cultured on Löwenstein-Jensen solid 
medium and BACTEC mycobacterial growth indicator 
tube (Becton Dickinson) liquid medium.
Role of the funding source
The Intramural Research Program of the NIAID, US 
National Institutes of Health, was involved in study 
design, data collection, data analysis, data interpretation, 
the writing of the report, and in the decision to submit 
the paper for publication. No other funding sources were 
involved in any of these decisions.
Results
124 participants were enrolled from June 22, 2017, to Sept 
27, 2018, and completed the study as cured (remained 
sputum culture negative) 18 months later (by April, 2020), 
the baseline characteristics are shown in the table. Among 
these participants, 161 cavities were seen (appendix 4 p 7). 
115 (71%) of these 161 cavities were located in the apical S1 
and posterior S2 segments of the right and left upper 
lobes, with an additional 36 (22%) in the apical S6 segment 
of the lower lobes. More than 90% of cavities were 
located in these apical segments, consistent with the 
known predilection of cavities in reactivation tuberculosis.21 
Cavitary air volumes ranged widely from less than 1∙0 mL 
to 104∙5 mL (cavity volumes within individual segments 
were summed).
On baseline PET-CT scans of the 124 participants, 
nodular or consolidative lesions directly connected by 
thickened or inflamed bronchi to cavities were seen 
in 121 (98%) instances. Representative participants are 
shown in figure 1. The patient in figure 1A has a 
multi-lobed cavity in the right upper lobe segment S2. 
Thickened and inflamed bronchi can be traced from this 
cavity to consolidated lesions in dependent areas of the 
lungs in the right upper lobe S3 segment and the right 
middle lobe S4 and S5 segments, showing potential 
gravitational spread of disease through the bronchi. 
Figure 1B shows a patient with thickened bronchi 
Total 
(n=124)
No new or 
expanded lesion 




at week 4  
(n=21)
p value*
Sex ·· ·· ·· 0·61
Female 37 (30%) 32 (31%) 5 (24%) ··
Male 87 (70%) 71 (69%) 16 (76%) ··
Age, years 34·3 (18·6–69·2) 33·6 (18·6–69·2) 37·8 (21·0–62·0) 0·11
Weight, kg 56·9 (10·4) 56·8 (10·5) 57·6 (10·0) 0·73
Body-mass index 20·2 (3·2) 20·2 (3·2) 20·3 (3·2) 0·90
Current smoker† 59/86 (69%) 48/72 (67%) 11/14 (79%) 0·57
Previous smoker (not current smokers 
but report a history of smoking)†
27/86 (31%) 24/72 (33%) 3/14 (21%) 0·53
Duration of smoking, years 15·7 (0·7–42·0) 15·5 (0·7–42·0) 15·6 (1·0–30·0) 0·97
Cavities ·· ·· ·· 0·0050
0 9 (7%) 9 (9%) 0 ··
1 76 (61%) 68 (66%) 8 (38%) ··
≥2 39 (31%) 26 (25%) 13 (62%) ··
Total cavity volume, mL 14·9 (20·3) 13·4 (19·2) 22·4 (24·2) 0·12
Country, n ·· ·· ·· 0·034
South Africa 87 (70%) 68 (66%) 19 (90%) ··
China 37 (30%) 35 (34%) 2 (10%) ··
Data are n (%), mean (range), mean (SD), or n/N (%). *t test for continuous variables and χ² or Fisher’s exact test for 
categorical variables. †Missing values are because some participants did not declare smoking status.
Table: Baseline characteristics of the 124 participants included in the study
See Online for appendix
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connecting an apical left S1–2 cavity with a non-cavitary 
lesion in S3 and an inflamed left lower lobe bronchus 
leading to an area of consolidation in the left lower lobe. 
Figure 1C shows a patient with a large posterior 
right upper lobe S2 segment cavity leading to large 





Figure 1: Examples of tuberculosis bronchial spread patterns on PET-CT scans with 3D renderings
Images are of baseline scans unless otherwise noted. (A) Right upper lobe cavity drains down the S2 segment bronchus (blue arrow), across to the S3 segment bronchus 
(red arrow), and down the right bronchus intermedius (green arrow) to the S4 segment bronchus (yellow arrow), with spread of disease to those segments. The S2 
segment lesion is red with a green cavity, S3 segment is yellow, and S4–5 segments are purple. (B) Bronchus (blue arrow) drains left S1–2 segment cavity straight down 
towards the left main bronchus (green arrow), branching to the S3 segment bronchus (yellow arrow) and down into the lower lobe (red arrow) to cause disease distal 
to those bronchi. In the 3D rendering, the S1–2 segment is orange with a green cavity, S3 segment is pink, and lower lobe disease is blue. (C) A bronchus (blue arrow) 
is visualised exiting the right S2 segment cavity, connecting down towards the right main bronchus (green arrow), with the S3 segment bronchus (red arrow) 
shooting off to cause disease anteriorly. S6 segment bronchus (purple arrow) comes off the right lower lobe bronchus and branches into the S6 segment (purple arrow) 
leading to disease in the apex of the right lower lobe. S7 bronchus (yellow arrow) and S10 bronchus (black arrow) are clearly outlined, leading to disease in those 
respective segments. In the 3D rendering, the S2 segment is pink with yellow cavity, the S3 segment is green, and the S6 and S10 segments are orange. (D) At baseline 
(top row), there are two cavities in the right upper lobe and another in the apical S6 segment of the right lower lobe. One or more of these spread tuberculosis bronchially 
down the right main bronchus (green arrow) to cause disease in the right lower lobe S7 and S8 segments. The left upper lobe is minimally involved at baseline with new 
or expanding S3 lesions appearing at week 4 (bottom row). At baseline, the right main bronchus inflammation from the right sided cavities spreads to the carina (green 
arrow). At week 4, the left main bronchus connects to the left S3 segment bronchi (blue arrows) and leads directly into the new or expanding lesion. The left S3 segment 
bronchus leading to the lesion was not well visualised at baseline, suggesting they became more inflamed by week 4, possibly from the increased bronchial spread. 
Bronchial spread across the carina like this could occur in a patient who sleeps on their left side at night. 3D=three-dimensional.
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S3 segment and the apical S6 segment of the right lower 
lobe. In figure 1D, an inflamed right main bronchus at 
baseline connects two cavities in the right upper lobe 
with a large consolidation in the right lower lobe S7–8. A 
cavity in the apical right lower lobe S6 segment probably 
also contributed to the bronchial spread pattern in right 
lower lobe S7–8. There also appears to be bronchial 
spread of disease from the right side to the left upper 
lobe S3 segment at baseline but with increased spread 
noted at week 4 of treatment. Despite this apparent 
worsening of disease on treatment, this patient was 
subsequently cured. Additional examples of bronchial 
spread patterns are shown in appendix 4 (pp 8–11). In 
32 (26%) of the 124 participants, the bronchial spread 
pattern appeared to originate in a consolidated lesion 
without a visualised cavity or with a very small (<1 mL) 
cavity (appendix 4 p 10).
Across all 124 participants, we identified 490 non-
cavitary consolidations connected to 161 cavitary lesions 
by thickened or inflamed bronchi. The most common 
pattern of apparent bronchial spread was from the apical-
posterior S1–2 segments to the anterior S3 segment in 
both left and right lung lobes (figure 2A). The second 
most common pattern of bronchial spread was 
from S1–2 to S4 and S5, the right middle lobe and left 
lingula shown in figure 2B. Spread from S1–2 to 
the apical segment of the lower lung, S6 was also 
frequently observed (figure 2C). Spread to the lower lobe 
from S1–2 was less common but still seen (figure 2D). 
Additional bronchial spread patterns are shown in 
appendix 4 (pp 12–13). Of the total 161 cavities identified, 
the 151 (94%) apical segment (S1–2 and S6) cavities and 
the bronchial segments to which they spread their disease 
are described in appendix 4 (pp 2–3). The remaining 
ten (6%) cavities are described in appendix 4 (pp 4–5). 
Disease spread predominantly to the ipsilateral lung but 
spread to the contralateral upper lobe was also seen 
(appendix 4 pp 2–3). To provide further evidence that 
inferior, dependent spread was more likely than superior 
spread, we analysed the likelihood of spread from an 
S6 segment cavity to inferior segments (ipsilateral S4–10) 
or superior segments (ipsilateral S1–3 or any contralateral 
segment). We chose S6 segment cavities to model because 
S1–2 segment cavities can only spread inferiorly. Spread 
of lesions was significantly more likely to inferior, 
dependent segments of the lung (55 [64%] of 86), than to 
superior segments (31 [36%] of 86, p=0∙013).
Intense FDG uptake (standardised uptake value >3) was 
observed in the bronchial lumen of ten (8%) of 
124 participants. This finding could represent bronchial 
spread of liquefied cavitary contents or its associated 
inflammation, or both. Figure 3 shows four examples of 
clearly inflamed bronchi connecting cavities with other 
consolidations, travelling up the trachea, and even crossing 
the carina. Bronchial spread across the carina could be 
dependent spread in a person who tends to sleep on their 
side at night, and has been previously described from 
autopsy specimens.7 On occasion, bronchial spread 
patterns appear to travel from an inferior cavity to a 
superior segment, which could possibly occur via 
aspiration of bacilli backwards (described historically9), or 
with coughing, with liquefied material travelling superiorly 
in a bronchus other than the trachea.
On the week 4 scans, 21 (17%) of 124 participants 
developed a total of 26 new or expanding lesions that were 
not present on their baseline scans with a direct bronchial 
connection to a superior cavity (appendix 4 pp 2–5). Among 
these 21 participants, those with new or expanding lesions 
were significantly more likely to have two or more cavities 
(compared with zero or one cavity, p=0∙0046) and to be 
from South Africa (compared with China, p=0∙034; table). 
Both cavity number and country remained significant with 
regard to developing a new or expanded lesion at week 4 in 
the final multivariate logistic regression model (cavity ≥2, 
odds ratio [OR] 4∙79 [95% CI 1∙78–13∙70], p=0∙0024; South 
Africa, 4∙86 [1∙25–32∙40], p=0∙045; appendix 4 p 6). An 
example of an expanding lesion is shown in figure 1D, in 
Figure 2: Ipsilateral bronchial spread pathways for apical segments
3D renderings of the source (cavitary) pulmonary segment (red), the bronchial spread pathway (orange), and the 
destination pulmonary segment (yellow) of selected bronchial spread pathways. The numbers indicate the total 
occurrences (baseline and week 4) of this pattern among the 124 participants analysed, with the number of new 
week 4 occurrences (subset of total). (A) Right lung segments S1–2 to right S3 and left lung segments S1–2 to 
left S3. (B) Right S1–2 to right S4–5 and left S1–2 to left S4–5. (C) Right S1–2 to right S6 and left S1–2 to left S6. 
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which the left upper lobe infiltrate present at baseline is 
expanded at week 4. Examples of new lesions that appear 
at week 4 are shown in figure 4. These new or expanding 
lesions originated from an apical S1–2 or S6 cavity except 
for one, which spread from a left upper lobe S3 segment 
cavity to the right upper lobe S3 segment (appendix 4 pp 4–5). 
21 (81%) of 26 new or expanding lesions originated from 
an apical S1–2 cavity and seven (27%) resulted in a lesion 
in the contralateral, previously unaffected lung from the 
originating cavitary lesion and, therefore, must have 
traversed the carina. Despite this seeming worsening 
of disease, all these participants were subsequently cured. 
In a microbiological analysis of solid culture results 
(cultures grown on Löwenstein–Jensen medium), 19 (90%) 
of 21 participants with new or expanding week 4 lesions 
sputum culture converted to negative by week 8, compared 
with 98 (95%) of 103 participants without new or expanding 
lesions (log-rank p=0∙18). Week 8 liquid culture conversion 
rates by mycobacterial growth indicator tube between 
participants with or without new or expanding week 4 
lesions also did not differ (log-rank p=0∙44).
Discussion
This observational analysis of the baseline and week 4 
PET-CT scans of the first 124 participants to complete the 
PredictTB trial and be cured of tuberculosis supports 
historical descriptions of reactivation tuberculosis, in 
which cavities are the source of bronchial spread of 
disease to consolidative lesions in dependent portions of 
the lungs. 98% of the participants in this cohort had 
bronchial thickening that characterises the bronchial 
spread patterns on baseline PET-CT scans. Only three 
participants with relatively mild disease did not have any 
bronchial thickening. The flow of inflammatory debris 
through the thickened bronchi is not visualised in most 
of the PET-CT scans but ten (8%) participants in this 
cohort did have clearly inflamed bronchi, evidenced by 
FDG PET uptake in addition to thickened bronchi, into 
other parts of the lung and even up the trachea, consistent 
with expulsion of liquefied phlegm through coughing 
(figure 2). Phlegm is filled with neutrophils,22 which take 
up FDG. Additional bronchial spread patterns with 
thickened bronchi persisted even 4 weeks into treatment 
A B C
D
Figure 3: Examples of bronchial inflammation on baseline PET-CT scan
(A) Inflammation from right S2 segment cavity flows down bronchus, which is better seen on CT alone (black and white image), into the right main bronchus and 
trachea. (B) Inflammation from left upper lobe cavities flows down into the left main bronchus. Although inflammation is not visualised crossing the carina, there is a 
direct bronchial connection to right S2 and S3 segment lesions. (C) Right lower lobe S7 segment consolidation with inflammation travelling up the right main 
bronchus and trachea to the pharynx (inset image shows the the trachea to pharynx; black and white image is CT alone). (D) Right and left S3 segment cavities with 
bronchial inflammation connecting the two across the carina, spreading inferiorly to the left S6 segment. Figures A–C are from the PredictTB study. Figure D is from a 
patient in a different study (NexGen EBA: Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis, NCT02371681).
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in a minority (21 [17%]) of the 124 participants, appearing 
as new or expanded lesions (figure 1D, figure 4), which 
was more likely to occur in participants with two or more 
cavities at baseline (compared with ≤1 cavity) and among 
those from South Africa (compared with China).
Multiple radiological descriptions of tuberculosis have 
been published, with evidence for bronchogenic spread 
of tuberculosis seen on CT scans described as 2–4 mm 
centrilobular nodules and linear branching opacities 
around terminal bronchioles (tree-in-bud sign).23,24 
Although these findings might be evidence of local bron-
chial spread of tuberculosis, the distant spread to other 
ipsilateral or contralateral pulmonary segments from 
cavities via the bronchi has not, to our knowledge, been 
previously described radiologically, including descriptions 
of FDG PET uptake within the bronchi. Endobronchial 
tuberculosis has been well described and might affect 
more than half of patients with acute pulmonary 
tuberculosis. Endobronchial tubercu losis is primarily 
diagnosed on bronchoscopy and has a variable appearance, 
ranging from bronchial mucosal oedema or hyperaemia 
to ulcerative or mass lesion, or both, with the main 
complication being bronchial stenosis.25 It is probable that 
some of our participants had endobronchial tuberculosis 
but, as we did not do any bronchoscopies, we are unable 
to determine which participants were affected and the 
relationship of endobronchial tuberculosis with the 
bronchial spread patterns that we describe.
Bronchial spread patterns of tuberculosis are present 
in most participants at baseline, which suggests that 
bronchial spread occurs in the natural history of untreated 
pulmonary tuberculosis. At week 4 of treatment, however, 
new or expanding lesions were seen in 21 (17%) of 
124 cured participants, particularly those with two or more 
cavities at baseline and those from South Africa. The 
finding that participants with more cavities had additional 
bronchial spread patterns is consistent with cavities being 
the source of these patterns. Why cavity number but not 
volume was associated with bronchial spread patterns is 
Figure 4: Representative examples of new lesions on the W4 PET-CT scan 
with 3D renderings
(A) Large right upper lobe cavity (red) with surrounding dense consolidation 
(green) and smaller left segments 1–3 cavities (pink) with surrounding 
consolidation (blue). All cavities shrank by W4. There was a new left side lingular 
infiltrate (blue arrows, green-brown lesion on 3D rendering) at W4 that was not 
present at W0. (B) At baseline, there was a large posterior left upper lobe S1–2 
cavity (red) with small anterior S3 cavity (red) at baseline and associated 
consolidation (green) primarily in left S1–2 down to the lingula S4–5. There was 
also an extensive left lower lobe consolidation (yellow) as well. At W4, left S1–2 
segment cavity had decreased in size but with markedly increased PET uptake 
around it. Left lower lobe consolidation, however, had improved. There was a 
new left S3 segment consolidation (blue arrows, pink lesion on 3D rendering) 
that was not present at baseline. (C) At baseline, there were cavities (red) with 
associated consolidations in the right upper lobe, apex of the left lower lobe, and 
in the left base. At W4, all of these had improved but there was a new left 
lingular lesion (blue arrows, blue lesion on 3D rendering) that was not present at 
baseline. (D) At baseline, disease was confined to the right upper lobe with a 
S1 cavity, surrounding consolidation, and spread of disease to the S3 segment. 
At W4, there were two new foci of nodular disease (blue arrows, purple 
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not clear and needs to be further explored. Additional 
analyses are also needed to understand why South African 
participants had more bronchial spread patterns than 
Chinese participants. Some of these new or expanding 
lesions could be subclinical paradoxical reactions to 
treatment rather than true spread of disease. A review of 
paradoxical tuberculosis reactions in patients without HIV 
found the prevalence to be between 2–23%.26 Alternatively, 
bronchial spread after the start of treatment might be a 
chemical pneumonitis reaction to released bacterial 
antigen than actual disease spread, which has also been 
described historically,7 and might explain why bronchial 
spread patterns at week 4, and possibly even at month 6,19 
might not indicate a worse prognosis. Sputum culture 
conversion results being similar between patients with 
and without new or expanding week 4 lesions support this 
explanation. More definitive analyses of how bronchial 
spread patterns associate with final treatment outcomes, 
cavity number and volume, and country will require 
including participants with poor outcomes, which will be 
done at the end of the parent PredictTB trial.
We believe that the bronchial thickening seen on 
PET-CT scans is caused by the flow of cellular debris and 
possibly infected neutrophils resulting from the host’s 
inflammatory response to necrotic lesions that connect 
to a bronchus and become cavities. One limitation to this 
conclusion, however, is that we do not have histological 
evidence of bronchial spread, and that what is being 
shown on the PET scans is inflammation of blood or 
lymphatic vessel walls, which travel along the bronchi. 
Although M tuberculosis bacilli are known to spread via 
the vasculature or lymphatics, the bronchial spread 
patterns we see, predominantly dependent spread to 
different ipsilateral or contralateral lung lobes, are not 
consistent with vascular or lymphatic seeding. 
Haematogenous dissemination, if slight, might lead to 
scattered foci of infection in the lungs, whereas heavy 
dissemination would lead to miliary tuberculosis. Neither 
type of dissemination should have a distribution defined 
by bronchial anatomy with primarily dependent spread. 
Lymphatic spread would seed bacilli proximally, typically 
infecting the hilar lymph nodes. Seeding ipsilateral lung 
lobes or crossing the carina to the contralateral lung 
would require first proximal then distal movement of 
bacilli via the lymphatics, which would be unlikely. Such 
movement, however, is consistent with direct, dependent 
bronchial spread of necrotic material containing 
M tuberculosis bacilli, for which there is abundant 
historical histological support. Another limitation of our 
study is that with static radiology images, connections 
between lesions can be seen but the directionality of the 
spread, or even whether there is any spread at all, cannot 
be definitely concluded. However, cavities on baseline 
chest x-ray have long been associated with poor treatment 
outcomes in multiple studies.27–30 In our study, multiple 
baseline cavities (≥2) are also associated with a 
significantly increased odds of a new or expanding lesion 
at week 4. These associations, along with pathology data 
from before the 1950s, support the cavitary origin of 
bronchial spread. The historical descriptions also include 
cases of bronchial spread patterns originating in 
consolidations without a visualised cavity or with a very 
small (<1 mL) cavity,8,9 which was seen in 26% of our 
participants.
The concept of bronchial spread from cavities in 
pulmonary tuberculosis that was extensively described 
in the pre-antibiotic era has been mostly lost in the 
intervening 60 years or so because of the scarcity of 
human autopsy specimens and subsequent animal 
models that do not completely recapitulate human 
disease.31 However, pulmonary PET-CT scans show 
changes consistent with bronchial spread of tuberculosis 
from cavities in almost all participants at baseline and 
continued bronchial spread patterns in a minority, 
particularly among those with two or more cavities, even 
4 weeks after starting treatment. This finding suggests 
that cavities might spread tuberculosis disease to other 
parts of the lungs through the bronchi and specifically 
targeting treatment to cavities might be more important 
than previously realised. Not all drugs penetrate and 
sterilise cavities well32 so those that do might be more 
effective to cure disease and prevent relapse. A better 
understanding of cavitary lesion dynamics and the 
viability of M tuberculosis within cavities might provide 
an effective biomarker of cure. Additionally, new or 
expanded nodular or consolidative lesions that appear on 
radiology after starting treatment might not always 
indicate disease worsening or drug resistance. Additional 
studies with more participants, especially those with 
poor outcomes, are needed to support these findings. 
After the overall PredictTB study has concluded, analyses 
will be done to understand more fully these bronchial 
spread patterns and their associations with final 
treatment outcomes.
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